Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
6.83
+0.07 (1.04%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Omeros Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
202
Market Cap
393.67M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
OMER News
- 7 days ago - Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight - Benzinga
- 8 days ago - Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program - Business Wire
- 10 days ago - Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases - Business Wire
- 18 days ago - Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results - Business Wire
- 22 days ago - Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings - Benzinga
- 23 days ago - Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 - Business Wire
- 4 weeks ago - Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program - Business Wire